UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | M | R | S | T | W
Number of items: 22.


Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Garman, EF; Gibson, AE; (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J MED CHEM , 43 (15) 2797 - 2804.

Azzabi, AS; Calvert, AH; Verrill, M; Kelly, C; Lind, MJ; Newell, DR; Griffin, MJ; (2000) Phase I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clinical Cancer Research , 6 539 - ?.


Bentley, J; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Endicott, JA; Gibson, AE; (2000) Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research , 6 328 - ?.

Boddy, AV; Griffin, MJ; Wright, JG; Sludden, JA; Thomas, HD; Fishwick, K; Plummer, R; (2000) Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer , 83 203 - ?.


Calabrese, CR; Curtin, NJ; Canan-Koch, SS; Batey, MA; Thomas, HD; Kyle, S; Wang, LZ; (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clinical Cancer Research , 6 150 - ?.

Calvert, P; Jayson, G; Atkinson, R; Ganesan, T; Cervantes-Ruiperez, A; Vasey, P; Adams, M; (2000) Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane. Annals of Oncology , 11 372P - ?.

Calvert, PM; O'Neill, V; Azzabi, A; Hughes, A; Plummer, R; Twelves, C; Robinson, A; (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. Clinical Cancer Research , 6 575 - ?.

Curtin, NJ; Calvert, AH; Canan-Koch, S; Durkacz, BW; Griffin, RJ; Golding, BT; Hostomsky, Z; (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clinical Cancer Research , 6 205 - ?.


De Silva, IU; McHugh, PJ; Clingen, PH; Hartley, JA; (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. MOL CELL BIOL , 20 (21) 7980 - 7990.


Friedman, HS; Kerby, T; Calvert, H; (2000) Temozolomide and treatment of malignant glioma. CLIN CANCER RES , 6 (7) 2585 - 2597.


Griffin, RJ; Arris, CE; Bleasdale, C; Boyle, FT; Calvert, AH; Curtin, NJ; Dalby, C; (2000) Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine. J MED CHEM , 43 (22) 4071 - 4083. 10.1021/jm000961o.

Griffin, RJ; Arris, CE; Calvert, AH; Curtin, NJ; Jewsbury, P; Endicott, JA; Gibson, AE; (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society , 219 296 - MEDI.


Hargreaves, RHJ; Hartley, JA; Butler, J; (2000) Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. FRONT BIOSCI , 5 E172 - E180.

Hooshmand-Rad, R; Hajkova, L; Klint, P; Karlsson, R; Vanhaesebroeck, B; Claesson-Welsh, L; Heldin, CH; (2000) The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in. Journal of Cell Science , 113 207 - 214.

Hughes, AN; Griffin, MJ; Newell, DR; Calvert, AH; Johnston, A; Kerr, B; Lee, C; (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.


Maini, MK; Gudgeon, N; Wedderburn, LR; Rickinson, AB; Beverley, PCL; (2000) Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J IMMUNOL , 165 (10) 5729 - 5737.

Meyer, T; Rustin, GJ; (2000) Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer , 82 (9) pp. 1535-1538. 10.1054/bjoc.2000.1174.


Raymond, EE; Fumoleau, P; Roche, H; Schellens, JHM; Dittrich, C; Punt, CJA; Droz, JP; (2000) Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clinical Cancer Research , 6 315 - ?.


Smith, PG; Thomas, HD; Barlow, HC; Griffin, RJ; Golding, BT; Calvert, AH; Newell, DR; (2000) In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research , 6 445 - ?.

Stein, RC; Waterfield, MD; (2000) PI3-kinase inhibition: a target for drug development? Mol Med Today , 6 (9) pp. 347-357.


Thomas, HD; Lind, MJ; Ford, J; Bleehen, N; Calvert, AH; Boddy, AV; (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. CANCER CHEMOTH PHARM , 45 (4) 284 - 290.


White, AW; Almassy, R; Calvert, AH; Curtin, NJ; Griffin, RJ; Hostomsky, Z; Maegley, K; (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J MED CHEM , 43 (22) 4084 - 4097. 10.1021/jm000950v.

This list was generated on Sun Oct 23 03:29:42 2016 BST.